CG Oncology, Inc. (CGON) · Nov 6, 2026 · Earnings
Beat — EPS $(0.64) vs approximately $(0.83) consensus
CG Oncology’s earnings beat low expectations, but the company’s valuation story still hinges on PIVOT-006 data due in November.
CG Oncology is a late-stage clinical biotech trying to turn cretostimogene into a broad bladder-sparing treatment, with its biggest near-term proof point coming from the randomized Phase 3 PIVOT-006 trial. The company had previously targeted PIVOT-006 topline data for the first half of 2026, so saying the readout is now expected in November narrows the timing but also confirms a delay versus the earlier plan.
The quarter beat the published financial bar, but the financials are not the core story. GAAP EPS was $(0.64), better than the roughly $(0.83) consensus, while revenue of $1.604 million exceeded the roughly $0.548 million estimate. That is a clean earnings beat, but CG Oncology remains pre-commercial: revenue is immaterial relative to its clinical spending, and the company’s value still depends primarily on trial results and regulatory execution.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Total revenues (Income Statement) | $1.604M | $1.666M | $0.548M |
| Net loss (Income Statement) | $(56.9M) | $(43.8M) | |
| Net loss per share (Income Statement) | $(0.64) | $(0.57) | $(0.83) |
| R&D expenses (Income Statement) | $39.2M | $27.9M | |
| Cash, equivalents and marketable securities (Balance Sheet) | $984.5M |
Operating losses are widening as the company funds the late-stage push. R&D rose to $39.2 million from $27.9 million as clinical-trial, manufacturing and headcount costs increased, while the quarterly net loss expanded to $56.9 million from $43.8 million. That spending is consistent with an approaching data and regulatory cycle, but it means the earnings beat does not represent improving underlying profitability.
The balance sheet removes near-term financing pressure rather than creating a new catalyst. Cash and marketable securities were $984.5 million at September 30, down from about $1.0 billion at June 30, and management reiterated funding through 2029. 〔0〕 The runway is important because it lets CG Oncology reach the upcoming readouts and planned BLA work without an obvious need for fresh capital, but this was already broadly established in the prior quarter.
The decisive information is still ahead, not in this quarter’s numbers. Management expects PIVOT-006 topline data in November and 12-month data from BOND-003 Cohort P and CORE-008 Cohort CX in December. 〔1〕 Those readouts will determine whether cretostimogene’s evidence supports expansion across more NMIBC patient groups; this filing mainly confirms the schedule and preserves the cash cushion.
Bottom line: CG Oncology delivered a modest earnings beat and remains well funded, but the quarter barely changes the business case. The real test is the delayed-but-imminent PIVOT-006 readout, followed by December durability data.
PIVOT-006 topline data, November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!